{
  "abstract": "Background Breast cancer (BC) is the most commonly diagnosed cancer among women, with 30% of cases occurring at age ≥70 years (70+). Because patients 70+ are underrepresented in BC clinical trials, real-world data may help fill treatment knowledge gaps for this population. Patients and methods PalomAGE is a French observational, multicentre, prospective study assessing the real-world feasibility of ET + palbociclib in women 70+ with hormonal receptor-positive/HER2-negative (/HER+/HER2-) locally advanced/metastatic BC (ABC). The primary endpoint was palbociclib permanent discontinuation rate at 18 months. Secondary endpoints included time to treatment failure (TTF), real-world progression-free survival (rwPFS), health-related quality of life (HRQoL) and geriatric status (G8 and G-CODE). Here, we report results from the endocrine-sensitive cohort, using ET + palbociclib as first-line treatment. Results From October 2018 through December 2020, 412 patients were enrolled. Of these, 382 received ≥1 cycle of palbociclib. With a median follow-up of 25.2 months, the 18-month palbociclib permanent discontinuation rate was 41%. The median TTF and rwPFS were 23.0 and 30.4 months, respectively. Palbociclib dose reduction and permanent discontinuation due to adverse events occurred in 35% and 11% of patients, respectively. There were no new safety signals and HRQoL remained stable throughout treatment. An altered G8 (≤14/17) at baseline was an independent factor for palbociclib discontinuation by multivariate analysis. Conclusion This analysis showed that first-line ET + palbociclib is feasible, well-tolerated and maintains HRQoL in women 70+ with endocrine-sensitive HR+/HER2- ABC, consistent with results from the general adult population. The G8 tool may help identify vulnerable older patients needing further geriatric assessment.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 22,
  "authors": [
    {
      "name": "E. Carola"
    },
    {
      "name": "P. Caillet"
    },
    {
      "name": "C. Falandry"
    },
    {
      "name": "L. Tassy"
    },
    {
      "name": "E. Paillaud"
    },
    {
      "name": "M. Pulido"
    },
    {
      "name": "G. Rochette de Lempdes"
    },
    {
      "name": "M. Bringuier"
    },
    {
      "name": "N. Jovenin"
    },
    {
      "name": "A. Boudrant"
    },
    {
      "name": "J. Grosjean"
    },
    {
      "name": "C. Chakiba-Brugere"
    },
    {
      "name": "O. Guillem"
    },
    {
      "name": "A C Hardy Bessard"
    },
    {
      "name": "H. Orfeuvre"
    },
    {
      "name": "E. Legouffe"
    },
    {
      "name": "Y. Brault"
    },
    {
      "name": "C. Chen"
    },
    {
      "name": "A. Coumert"
    },
    {
      "name": "M. Decrop"
    },
    {
      "name": "F. Bouteiller"
    },
    {
      "name": "E. Brain"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/fr616vqg0ddfq.bib",
  "cited_by": 1,
  "doi": "10.1016/j.breast.2026.104879",
  "fulltext_url": null,
  "id": "fr616vqg0ddfq",
  "issns": [
    "0960-9776",
    "1532-3080"
  ],
  "landing_url": "https://hal.science/hal-05866217v1",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "hal",
      "1.sdv.can"
    ],
    [
      "openalex",
      "2730|Advanced Breast Cancer Therapies"
    ]
  ],
  "openalex": "W7171844477",
  "pdf_url": "https://hal.science/hal-05866217/document",
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-16",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/fr616vqg0ddfq.ris",
  "sources": [
    {
      "first_seen": "2026-11-16T12:20:43Z",
      "native_id": "hal-05866217",
      "source": "hal",
      "url": "https://hal.science/hal-05866217v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "hal:0.sdv",
      "subfield": "general"
    },
    {
      "field": "medicine",
      "origin": "hal:1.sdv.can",
      "subfield": "oncology"
    }
  ],
  "title": "Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced/metastatic breast cancer in women aged 70 years and older – final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study",
  "title_text": "Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced/metastatic breast cancer in women aged 70 years and older – final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T12:20:43Z",
  "url": "https://research.draconitic.com/paper/fr616vqg0ddfq",
  "venue": "The Breast",
  "versions": []
}